Jump to content

Azumolene

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Entranced98 (talk | contribs) at 23:34, 5 April 2023 (Importing Wikidata short description: "Chemical compound"). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Azumolene
Identifiers
  • 1-[(E)-[5-(4-bromophenyl)-1,3-oxazol-2-yl]methylideneamino]imidazolidine-2,4-dione
CAS Number
PubChem CID
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H9BrN4O3
Molar mass349.144 g·mol−1
3D model (JSmol)
  • C1C(=O)NC(=O)N1/N=C/C2=NC=C(O2)C3=CC=C(C=C3)Br
  • InChI=1S/C13H9BrN4O3/c14-9-3-1-8(2-4-9)10-5-15-12(21-10)6-16-18-7-11(19)17-13(18)20/h1-6H,7H2,(H,17,19,20)/b16-6+
  • Key:SEGCNGONCZQFDW-OMCISZLKSA-N

Azumolene is an experimental drug which is a derivative of dantrolene. In animal studies, azumolene showed similar efficacy to dantrolene at controlling symptoms of malignant hyperthermia but with better water solubility and lower toxicity, albeit with lower potency.[1][2][3]

References

  1. ^ Sudo RT, Carmo PL, Trachez MM, Zapata-Sudo G (March 2008). "Effects of azumolene on normal and malignant hyperthermia-susceptible skeletal muscle". Basic & Clinical Pharmacology & Toxicology. 102 (3): 308–16. doi:10.1111/j.1742-7843.2007.00156.x. PMID 18047479.
  2. ^ do Carmo PL, Zapata-Sudo G, Trachez MM, Antunes F, Guimarães SE, Debom R, et al. (2010). "Intravenous administration of azumolene to reverse malignant hyperthermia in swine". Journal of Veterinary Internal Medicine. 24 (5): 1224–8. doi:10.1111/j.1939-1676.2010.0556.x. PMID 20584138.
  3. ^ Thota S, Rodrigues DA, Pinheiro PS, Lima LM, Fraga CA, Barreiro EJ (September 2018). "N-Acylhydrazones as drugs". Bioorganic & Medicinal Chemistry Letters. 28 (17): 2797–2806. doi:10.1016/j.bmcl.2018.07.015. PMID 30006065.